Medical Product Alert: Falsified Cancer Medicine IBRANCE (Palbociclib)

The Ministry of Health, via its Chemistry, Food and Drugs Division (CFDD), is advising of the WHO Medical Product Alert concerning falsified IBRANCE (palbociclib) capsules. The product is a cancer medicine used for the treatment of certain types of breast cancer in adults.

In a Media Release today (Tuesday 3rd February, 2026), the Ministry said the falsified products deliberately misrepresent identity, composition and source, and the genuine manufacturer, Pfizer, has confirmed that the products mentioned in this alert are falsified. The WHO Alert stated that falsified IBRANCE (palbociclib) products have been detected in Côte d'Ivoire, Egypt, Lebanon, Libya and Türkiye.

According to the Ministry, “Laboratory testing conducted by the genuine manufacturer confirmed that the falsified products contained no active pharmaceutical ingredient. Since these falsified medicines lack the required active ingredient, they must be considered unsafe and their use can lead to treatment failure, uncontrolled progression of cancer and an increased risk of death.”

In addition, the Ministry notes that “multiple visual discrepancies were identified on the packaging. While some of the falsified products carried genuine lot numbers, they displayed abnormalities in packaging, serialisation and capsule printing.”

The product, IBRANCE (palbociclib) capsules, is registered for use in Trinidad and Tobago and therefore, out of an abundance of caution, the Ministry is advising persons who may be in possession of the following drug bearing lot numbers to discontinue use immediately and to return to the place of purchase, where possible.

The following features have been identified as signs of falsified IBRANCE (palbociclib) products:

Label abnormalities:

  • States “Manufactured by: Pfizer, PO Box 29387, Mission, KS 66201.”
  • Contains spelling errors or poor-quality printing.

Packaging discrepancies:

  • Security foil on the bottle displays the Pfizer logo in black ink.

Capsule irregularities:

  • Capsules marked with black ink “PBC 125” or have no markings at all.
  • Capsules appear in unusual colours (e.g., bright orange).


(Click/Tap Image To Enlarge)

Additional information can be obtained by contacting the Office of the Chemistry, Food and Drugs Division at 868-217-4664, Ext. 13121.

Please be guided accordingly.

Comments

Trending Right Now On Youthere1 News

49-Year-Old Man Shot Dead, Wife Wounded While Children Slept In Valencia Home — Police Investigating

NO Electricity On Tuesday In Parts of Diego Martin, Valsayn, St. Augustine, Claxton Bay, San Fernando, Barrackpore

T&TEC: NO Electricity On Monday In Parts of Couva And Manahambre

32-Year-Old Hairdresser Found Dead In Cunupia Apartment After Heated Dispute, Pregnancy Revelation

NO Electricity On Sunday In Parts of Port-of-Spain, Bamboo Village, Claxton Bay

NO Electricity On Wednesday In Parts of Maraval, Valencia, Curepe, Freeport, Tabaquite

Child Among FOUR (4) Shot Dead In Morvant Massacre — Police Investigating

NO Electricity On Thursday In Parts of Port-of-Spain, San Souci, Maloney, Marabella